Pulmonary pharmacology /

Pulmonary pharmacology / edited by W.S. Fred Wong.

Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthm...

Full description

Saved in:
Bibliographic Details
Online Access: Full Text (via ScienceDirect)
Other Authors: Wong, W. S. Fred
Format: Electronic eBook
Language:English
Published: [Place of publication not identified] : Academic Press, 2023.
Series:Advances in pharmacology ; volume 98
Subjects:
Pulmonary pharmacology.
Table of Contents:
  • Intro
  • Title page
  • Table of Contents
  • Advances in PHARMACOLOGY
  • Copyright
  • Contributors
  • Preface
  • Abbreviations
  • Chapter One: Genomic and non-genomic effects of glucocorticoids in respiratory diseases
  • Abstract
  • Abbreviations
  • 1 Introduction
  • 2 Genomic mechanisms of action: GR activation
  • 3 GR transactivation or transrepression-mediated mechanisms of action of GCs
  • 4 Non-genomic mechanisms of action of GCs
  • 5 Conclusion
  • Acknowledgements
  • References
  • Chapter Two: Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment
  • Abstract
  • Abbreviation
  • 1 Introduction
  • 2 IL-5
  • 3 Mepolizumab
  • 4 Reslizumab
  • 5 Benralizumab
  • 6 IL-4 and IL-13
  • 7 Dupilumab
  • 8 Future developments
  • 9 Conclusion
  • Conflicts of interest
  • References
  • Chapter Three: Phosphodiesterase inhibitors and lung diseases
  • Abstract
  • Abbreviations
  • 1 Introduction
  • 2 Conclusion
  • Conflict of interest statement
  • References
  • Chapter Four: Prospects for macrolide therapy of asthma and COPD
  • Abstract
  • Abbreviations
  • 1 Introduction
  • 2 Why asthma and COPD
  • 3 What non-antimicrobial macrolide actions are relevant
  • 4 Can antibiosis with macrolides be circumvented
  • 5 Conclusion
  • Acknowledgments
  • References
  • Note in proof
  • Chapter Five: Targeting the renin angiotensin system for respiratory diseases
  • Abstract
  • Abbreviations
  • 1 Introduction
  • 2 Tareting renin angiotensin system in asthma
  • 3 Targeting renin angiotensin system in COPD
  • 4 Targeting renin angiotensin system in pulmonary fibrosis
  • 5 Targeting renin angiotensin system in acute lung injury
  • 6 Conclusion
  • References
  • Chapter Six: Progress in the development of kinase inhibitors for treating asthma and COPD
  • Abstract
  • Abbreviations
  • 1 Introduction
  • 2 Conclusion
  • Conflict of interest statement
  • References
  • Chapter Seven: Anti-fibrotic strategies and pulmonary fibrosis
  • Abstract
  • Abbreviations
  • 1 Introduction
  • 2 IPF pathogenesis: Initiation of fibrogenesis
  • 3 Pathways implicated in fibrosis
  • 4 Growth factor and cytokine activation in IPF
  • 5 Mechanotransduction and Hippo activation
  • 6 Cellular players in IPF
  • 7 IPF models
  • 8 IPF drug treatment
  • 9 Recommended drugs for IPF: Pirfenidone and nintedanib
  • 10 Conclusion
  • References
  • Chapter Eight: Novel treatments against airway inflammation in COPD based on drug repurposing
  • Abstract
  • Abbreviations
  • 1 Introduction
  • 2 The novel pharmacologic targets
  • 3 Conclusion
  • Acknowledgements
  • References
  • Chapter Nine: Senotherapy for lung diseases
  • Abstract
  • Abbreviations
  • 1 Introduction
  • 2 Senotherapy for lung disease
  • 3 Conclusion
  • Conflict of interest
  • References
  • Chapter Ten: Delivery technology of inhaled therapy for asthma and COPD
  • Abstract
  • Abbreviations

Similar Items